| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 82249-0613-30 | 82249-0613 | Everolimus | Yulithira | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 11, 2026 | In Use | |
| 00069-0079-01 | 00069-0079 | Paclitaxel | Paclitaxel | 30.0 mg/5mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sep 30, 2011 | Dec 31, 2016 | No Longer Used |
| 16714-0465-01 | 16714-0465 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan 1, 2016 | Nov 30, 2018 | No Longer Used |
| 31722-0365-31 | 31722-0365 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Oct 15, 2024 | In Use | |
| 00069-0255-10 | 00069-0255 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Oct 14, 2024 | In Use | |
| 00527-1778-14 | 00527-1778 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Mar 23, 2016 | May 24, 2018 | In Use |
| 72485-0213-15 | 72485-0213 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Sep 4, 2020 | In Use | |
| 70860-0200-17 | 70860-0200 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Mar 24, 2017 | Nov 30, 2024 | No Longer Used |
| 52652-2001-06 | 52652-2001 | Methotrexate | Xatmep | 2.5 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Aug 13, 2018 | In Use | |
| 71288-0118-10 | 71288-0118 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | Jul 26, 2022 | Nov 19, 2026 | In Use |
| 72205-0117-28 | 72205-0117 | Sunitinib Malate | Sunitinib Malate | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Jun 1, 2025 | In Use | |
| 00409-4235-01 | 00409-4235 | DOCETAXEL | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jun 28, 2021 | In Use | |
| 51862-0086-51 | 51862-0086 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct 10, 2016 | Mar 31, 2019 | In Use |
| 83858-0103-60 | 83858-0103 | Dasatinib | PHYRAGO | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 1, 2024 | In Use | |
| 00703-4239-01 | 00703-4239 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Oct 23, 2014 | In Use | |
| 00378-5262-14 | 00378-5262 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jun 29, 2016 | Feb 28, 2018 | No Longer Used |
| 00143-9830-01 | 00143-9830 | Methotrexate | Methotrexate | 1.0 g/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous | Apr 25, 2017 | In Use | |
| 55150-0271-99 | 55150-0271 | Cyclophosphamide | Cyclophosphamide | 1.0 g/5mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Nov 20, 2023 | In Use | |
| 55390-0237-01 | 55390-0237 | Doxorubicin Hydrochloride | Adriamycin | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | May 1, 1996 | Jun 30, 2014 | No Longer Used | |
| 54868-5289-04 | 54868-5289 | Imatinib Mesylate | Gleevec | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Oct 7, 2005 | Jun 30, 2013 | No Longer Used | |
| 63020-0080-01 | 63020-0080 | Ixazomib | Ninlaro | 4.0 mg/1 | Chemotherapy | Proteasome Inhibitor | 20S | Oral | Nov 20, 2015 | Oct 31, 2023 | No Longer Used |
| 70377-0086-11 | 70377-0086 | Dasatinib | Dasatinib | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
| 62856-0714-30 | 62856-0714 | Lenvatinib | Lenvima | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, RET | Oral | Feb 13, 2015 | In Use | ||
| 00069-4037-01 | 00069-4037 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Mar 17, 2014 | Aug 31, 2025 | In Use |
| 00069-0151-11 | 00069-0151 | Axitinib | Inlyta | 5.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan 27, 2012 | In Use |
Found 12611 results — Export these results
Home